IN2014MN01488A - - Google Patents

Info

Publication number
IN2014MN01488A
IN2014MN01488A IN1488MUN2014A IN2014MN01488A IN 2014MN01488 A IN2014MN01488 A IN 2014MN01488A IN 1488MUN2014 A IN1488MUN2014 A IN 1488MUN2014A IN 2014MN01488 A IN2014MN01488 A IN 2014MN01488A
Authority
IN
India
Prior art keywords
mixture
subunits
subunit
mol
relative
Prior art date
Application number
Other languages
English (en)
Inventor
Laura Akullian
Gui Liu
Timothy B Lowinger
Dennis Mcgillicuddy
Cheri Stevenson
John Van Duzer
Mao Yin
Aleksandr Yurkovetskiy
Original Assignee
Mersana Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mersana Therapeutics Inc filed Critical Mersana Therapeutics Inc
Publication of IN2014MN01488A publication Critical patent/IN2014MN01488A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D303/00Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02Compounds containing oxirane rings
    • C07D303/12Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D303/00Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02Compounds containing oxirane rings
    • C07D303/12Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • C07D303/20Ethers with hydroxy compounds containing no oxirane rings
    • C07D303/22Ethers with hydroxy compounds containing no oxirane rings with monohydroxy compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
IN1488MUN2014 2011-12-23 2012-12-21 IN2014MN01488A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161580016P 2011-12-23 2011-12-23
US201261639654P 2012-04-27 2012-04-27
PCT/US2012/071477 WO2013096901A1 (fr) 2011-12-23 2012-12-21 Formulations pharmaceutiques pour conjugués de dérivé de fumagilline-phf

Publications (1)

Publication Number Publication Date
IN2014MN01488A true IN2014MN01488A (fr) 2015-04-17

Family

ID=48669583

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1488MUN2014 IN2014MN01488A (fr) 2011-12-23 2012-12-21

Country Status (9)

Country Link
US (1) US20130189218A1 (fr)
EP (1) EP2794582A1 (fr)
JP (1) JP2015503635A (fr)
KR (1) KR20140121827A (fr)
CN (1) CN104024236A (fr)
IN (1) IN2014MN01488A (fr)
TW (1) TW201332574A (fr)
UY (1) UY34542A (fr)
WO (1) WO2013096901A1 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10598653B2 (en) 2011-11-01 2020-03-24 Bionomics Inc. Methods of blocking cancer stem cell growth
AU2015339012B2 (en) 2014-10-31 2020-11-05 Abbvie Biotherapeutics Inc. Anti-CS1 antibodies and antibody drug conjugates
RU2017123942A (ru) 2014-12-09 2019-01-11 Эббви Инк. Ингибирующие bcl-xl соединения, обладающие низкой клеточной проницаемостью, и коньюгаты антитело-лекарственное средство, включающие их
CN113209306A (zh) 2014-12-09 2021-08-06 艾伯维公司 具有细胞渗透性的bcl-xl抑制剂的抗体药物缀合物
AU2016365117A1 (en) 2015-11-30 2018-05-31 Abbvie Biotherapeutics Inc. Anti-huLRRC15 antibody drug conjugates and methods for their use
CA3006596A1 (fr) 2015-11-30 2017-06-08 Abbvie Inc. Conjugues anticorps-medicaments anti-hulrrc15 et procedes d'utilisation de ces conjugues
EP3432925A4 (fr) 2016-03-22 2019-11-06 Bionomics Limited Administration d'un anticorps monoclonal anti-lgr5
WO2017201204A1 (fr) 2016-05-17 2017-11-23 Abbvie Biotherapeutics Inc. Conjugués anticorps-médicament anti-cmet et méthodes d'utilisation de ces conjugués
AU2017273871B2 (en) * 2016-06-03 2020-03-26 Novacyte Therapeutics Company.,LTD Polymer linkers and their uses
AU2017277534A1 (en) 2016-06-08 2019-01-03 Abbvie Inc. Anti-EGFR antibody drug conjugates
US20200002421A1 (en) 2016-06-08 2020-01-02 Abbvie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
JP2019524651A (ja) 2016-06-08 2019-09-05 アッヴィ・インコーポレイテッド 抗cd98抗体及び抗体薬物コンジュゲート
EP3835322A3 (fr) 2016-06-08 2021-10-06 AbbVie Inc. Anticorps anti-b7-h3 et conjugués anticorps-médicament
EP3468596A2 (fr) 2016-06-08 2019-04-17 AbbVie Inc. Anticorps anti-cd98 et conjugués anticorps-médicament
EP3468615A1 (fr) 2016-06-08 2019-04-17 AbbVie Inc. Conjugué médicament-anticorps anti-egfr
JP2019521106A (ja) 2016-06-08 2019-07-25 アッヴィ・インコーポレイテッド 抗egfr抗体薬物コンジュゲート
MX2018015285A (es) 2016-06-08 2019-09-18 Abbvie Inc Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
EP3468599A2 (fr) 2016-06-08 2019-04-17 AbbVie Inc. Anticorps anti-cd98 et conjugués anticorps-médicament
CA3098420A1 (fr) 2018-06-01 2019-12-05 Novartis Ag Molecules de liaison dirigees contre bcma et leurs utilisations
KR20210027410A (ko) * 2018-07-03 2021-03-10 페넥 파마슈티컬스, 인크. 무수 싸이오황산나트륨의 제형
MX2021009851A (es) 2019-02-18 2021-09-10 Lilly Co Eli Formulacion de anticuerpos terapeuticos.
EP3972993A1 (fr) 2019-05-21 2022-03-30 Novartis AG Domaines de cd58 variants et leurs utilisations
UY38701A (es) 2019-05-21 2020-12-31 Novartis Ag Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas
US20210040197A1 (en) 2019-08-08 2021-02-11 Regeneron Pharmaceuticals, Inc. Novel antigen binding molecule formats
JP2022553830A (ja) 2019-11-05 2022-12-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッド N末端scFv多重特異性結合分子
US20230090552A1 (en) 2020-01-08 2023-03-23 Synthis Therapeutics, Inc. Alk5 inhibitor conjugates and uses thereof
CN115315446A (zh) 2020-03-06 2022-11-08 Go医疗股份有限公司 抗糖-cd44抗体及其用途
CN116249549A (zh) 2020-03-27 2023-06-09 诺华股份有限公司 用于治疗增殖性疾病和自身免疫病症的双特异性组合疗法
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
JP2024512324A (ja) 2021-03-05 2024-03-19 ジーオー セラピューティクス,インコーポレイテッド 抗グリコcd44抗体およびその使用
CA3228178A1 (fr) 2021-08-05 2023-02-09 Go Therapeutics, Inc. Anticorps anti-glyco-muc4 et leurs utilisations
TW202325733A (zh) 2021-09-03 2023-07-01 美商Go治療公司 抗醣化-lamp1抗體及其用途
AU2022339667A1 (en) 2021-09-03 2024-04-11 Go Therapeutics, Inc. Anti-glyco-cmet antibodies and their uses

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5290807A (en) * 1989-08-10 1994-03-01 Children's Medical Center Corporation Method for regressing angiogenesis using o-substituted fumagillol derivatives
MX2010005857A (es) * 2007-11-28 2010-11-22 Mersana Therapeutics Inc Conjugados de analogos de fumagillina biodegradables biocompatibles.
CA2762877A1 (fr) * 2009-05-28 2010-12-02 Mersana Therapeutics, Inc. Conjugues de medicament/polyal comprenant des liants a taux de liberation variable

Also Published As

Publication number Publication date
CN104024236A (zh) 2014-09-03
US20130189218A1 (en) 2013-07-25
UY34542A (es) 2013-07-31
TW201332574A (zh) 2013-08-16
WO2013096901A8 (fr) 2014-08-07
EP2794582A1 (fr) 2014-10-29
WO2013096901A1 (fr) 2013-06-27
JP2015503635A (ja) 2015-02-02
KR20140121827A (ko) 2014-10-16

Similar Documents

Publication Publication Date Title
IN2014MN01488A (fr)
EA201390600A1 (ru) Терапевтические наночастицы с сополимерами с большим молекулярным весом
MX2018008061A (es) Profarmacos de peptido natriuretico tipo c (cnp) con porciones portadoras grandes.
MX347644B (es) Macromoleculas estrella para el cuidado personal y del hogar.
WO2012135025A3 (fr) Lipomères conjugués et utilisations associées
IN2014DN00101A (fr)
GB201008902D0 (en) Membrane enhanced polymer sythesis
EA201200617A1 (ru) Полимеры на основе циклодекстрина для доставки лекарственных средств
MX352245B (es) Formulacion farmaceutica que comprende una droga biofarmaceutica.
EP2555741A4 (fr) Composition pulvérisable comprenant un polymère chargé de poids moléculaire élevé
MX2012000575A (es) Conjugados de epsilon-polilisina y uso de los mismos.
BR112013028365A2 (pt) "composição líquida compreendendo adi, composto compreendendo adi ligada covalentemente através de grupo de ligação a polietilenoglicol e uso de adi no preparo de composição para tratamento de câncer".
DE602006020256D1 (de) Geringe mengen hochmolekularer polymere zur viskositätserhöhung bei wässrigen/wässrig-zweiphasigen flüssigkeiten
BRPI0621656B8 (pt) misturas binárias de ácido hialurônico e uso terapêutico destas
MX340118B (es) Composiciones para el cuidado del cabello.
IN2014CN03735A (fr)
EA201270186A1 (ru) Фармацевтические композиции, содержащие модифицированные фуканы, для использования при лечении фиброзных спаек и других нарушений
BR112014004644A2 (pt) polímeros funcionalizados com lactonas ou tiolactonas contendo um grupo amino protegido
WO2013186632A3 (fr) Conjugués de molécules biologiquement actives à des polymères fonctionnalisés
MX2014008373A (es) Conjugados antagonistas de integrina para suministro dirigido a celulas que expresan alfa-v-beta-3.
WO2013013753A3 (fr) Polymères et oligomères ayant des groupes latéraux fonctionnalisés
MX2012006265A (es) Formulaciones disacaridas hipersulfatadas.
BR112014016177A8 (pt) composição de cloreto de polivinila, tubo, calha ou tanque, uso de uma composição de pvc e uso de tubo, calha ou tanque
WO2011130716A3 (fr) Nanostructures contenant de la vitamine b12 pour l'administration facilitée de médicaments à travers des barrières biologiques
MX2013002324A (es) Aditivo de mateado y/o deslustrado para polimeros o mezclas de polimeros.